Should You Buy Tilray Stock Before July 15?

On July 15, the DEA will conclude a public hearing on moving cannabis from Schedule I to Schedule III, but the article stresses it won’t legalize marijuana or guarantee rescheduling. A Schedule III outcome would likely reduce punitive IRS Section 280E tax treatment for U.S. operators, though Tilray isn’t a direct near-term beneficiary since it lacks U.S. plant-touching operations. The piece argues Tilray’s ~ $265M in cash and marketable securities (plus ~$630M revenue in the first nine months of fiscal 2026) gives it flexibility, with the real upside tied to multi-year reform progress rather than a one-day headline pop.

Analysis

The market is likely to overprice the procedural event and underprice the winner-take-most mechanics. If policy advances, the first-order upside belongs to U.S. plant-touching operators via tax normalization; Tilray is more of a sentiment beta than a direct earnings beneficiary, so any rally in TLRY should be treated as a rerating of the whole cannabis complex rather than a fundamental inflection.

The more interesting second-order effect is capital migration: rescheduling would improve the funding profile of U.S. MSOs and pull relative multiples away from Canadian/adjacent names. For TLRY, a stronger balance sheet is only valuable if it can be deployed into accretive assets; otherwise it just buys time while competitors with direct U.S. exposure use better after-tax cash flow to reinvest faster.

Over 1-3 months, the key catalyst is not the hearing itself but whether it changes the probability distribution for actual rulemaking. If the record remains non-committal, the sector should fade; if the process shows a credible path to Schedule III, the better expression is long U.S. cannabis beta versus TLRY, with the structural view extending 6-18 months as lower tax drag improves consolidation odds and survival rates. The contrarian miss: this is not a binary legalization trade, and TLRY’s long-term equity value still depends more on execution and capital allocation than on one regulatory milestone.

Key Decisions for Investors

• Prefer a relative-value expression: long MSOS / short TLRY into the hearing window, targeting a 1-3 month re-rating spread if policy momentum improves; cut the pair if the hearing produces no actionable regulatory signal.
• Avoid chasing TLRY on headline volatility; if it spikes on the event, use rallies to trim or short for a fade back toward fundamental valuation because it lacks the direct 280E torque of U.S. MSOs.
• Set a watch alert for any formal DEA/HHS follow-through within 30-60 days; if the process stalls, expect the sector premium to compress quickly and maintain a bearish stance on the basket.
• If seeking upside optionality, use call spreads on a U.S. cannabis beta vehicle rather than TLRY outright, since the upside from rescheduling is asymmetrically concentrated in tax-affected operators.